Weight loss drug maker sinks 23% after new safety data spooks investors
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
Weight loss drug maker sinks 23% after new safety data spooks investors basliginda one cikan gelisme: While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.